Partners

Eli Lilly $250M Collaboration

AI + robotics-powered de novo small-molecule drug discovery for an undisclosed target. One of the largest AI pharma deals by a China-origin platform.

First HKEX Chapter 18C Listing

Listed June 2024 as the first specialized technology company under new HKEX rules. Retail subscription oversubscribed 100x+.

2 Science Papers Published Today (Mar 20, 2026)

Two brain science breakthroughs published simultaneously in Science: discovery of an emotional "gate" enabling "pain without depression", and decoding brain-skin communication pathways.

World-First Brain-Spine Interface — FDA Breakthrough Therapy

Fudan's ISTBI developed the world's first clinical Brain-Spine Interface for paralysis recovery, granted US FDA Breakthrough Therapy Designation in December 2025.

World's #2 Shipped AI Health Wearable Brand

ZenoWell has become the world's second-largest shipped AI health wearable brand globally, with devices sold in 50+ countries and 2M+ patient sessions recorded with zero serious adverse events.

Harvard, Cambridge & Heidelberg Research Collaborations

Strategic collaborations with Harvard University, University of Cambridge, and Heidelberg University advancing next-generation closed-loop neurotechnology from research to real-world application. BrainClos research systems used in clinical studies at these institutions.

OpenAI HealthBench #1 Globally

Baichuan-M3 scored 65.1 on HealthBench as of January 2026, surpassing GPT-5.2. The M3-Plus variant achieves the world's lowest medical AI hallucination rate at 2.6%.

Free API for All Medical Institutions

The "海纳百川" program offers free M3-Plus API access to all medical institutions, positioning Baichuan as healthcare AI infrastructure rather than a premium product.

China's First AI-Designed Drug in Phase III

MDR-001, an oral GLP-1 agonist for obesity/T2D, is the first small molecule designed entirely by AI to reach Phase III in China. The MOBILE trial (first patient dosed Feb 25, 2026) enrolled ~750 patients across 50 centers.

4.5 Years from Discovery to Phase III

Achieved discovery-to-Phase III in 4.5 years versus the industry standard of 7–10 years, demonstrating how AI can compress the drug development timeline without cutting corners on clinical rigor.

FDA Fast Track Designation for DF-003

DF-003 — a first-in-class oral ALPK1 inhibitor for ROSAH syndrome — received FDA Fast Track Designation in January 2026, accelerating development for this ultra-rare disease.

First Drug in FDA RDEP Pathway

DF-003 was accepted into the FDA Rare Disease Evidence Principles Process (RDEP) in March 2026, making it among the first drugs to enter this new ultra-rare disease regulatory pathway.

Anta First Mycelium Sneaker

Collaborated with Anta to produce the first mycelium-based sneaker (April 2025), proving bio-materials can meet performance standards of a major sportswear brand.

Carbon-Negative Certification

SGS-certified at -17 kg CO₂ per kg (ISO 14067) — not just carbon-neutral but actively carbon-negative. USDA Certified Biobased at up to 100%.

Inno-DrugAgent: Autonomous AI Scientist

An autonomous AI agent scientist capable of self-directed, human-interactive R&D automation — going beyond traditional tools to act as an independent research partner.

NVIDIA Inception Showcase 2023

Selected for NVIDIA's Inception program showcase, recognizing CarbonSilicon's GPU-accelerated drug discovery infrastructure.

World's First AI-Assisted Unmanned Drug Discovery Lab

Built for Insilico Medicine in Suzhou — a fully automated end-to-end drug discovery lab where robots handle all physical experimentation 24/7 with zero human intervention.

iMagicOS: 180+ Instrument Compatibility

Cloud operating system compatible with 180+ third-party instrument drivers, deployable in 1 hour, with unlimited high-throughput multi-task scheduling at <1 second latency.